Whitehawk Therapeutics Inc (WHWK) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-223.6%

-$3.86

vs $3.12 price

Levered DCF

-$4.05

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

6.55

Safe zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-7.33×	-1.34×	-0.84×	-4.77×	-1.95×	-70×	-5.67×
P/B	1.1×	1.63×	0.52×	1.82×	1.57×	-20.85×	-7.63×
P/S	20.96×	3.29×	2.27×	18.98×	191.29×	17.78×	92.6×
EV / EBITDA	-5.47×	-0.89×	0.1×	-4.28×	-1.78×	-104.33×	-5.09×
Gross margin	89.4%	-108.0%	-112.4%	-123.4%	-1656.3%	-2.9%	-1377.2%
Operating margin	-1601.1%	-259.6%	-295.4%	-411.9%	-9930.1%	-17.5%	-1624.8%
Net margin	-288.3%	-245.1%	-270.0%	-397.7%	-9829.5%	-23.9%	-1636.2%
Current ratio	10.26×	3.59×	4.72×	9.56×	9.9×	0.62×	0.64×
Debt / equity	0×	0.02×	0.01×	0.01×	0×	-0.82×	-0.93×
Interest coverage	0×	-438.04×	-311.4×	-272.53×	-167.24×	-3.13×	-144.99×
Dividend yield	0.0%	0.0%	0.0%	0.0%	2.1%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	-4.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-15.1%	-121.4%	-62.5%	-38.2%	-80.7%	28.0%	134.8%
Return on invested capital	-83.9%	-126.1%	-67.6%	-37.8%	-77.9%	122.6%	2004.8%
Return on assets	-13.7%	-90.6%	-49.7%	-32.8%	-69.7%	-18.5%	-73.6%
Free cash flow yield	-65.4%	-71.7%	-115.3%	-17.3%	-10.5%	-4.9%	-11.0%
Earnings yield	-13.8%	-74.6%	-119.2%	-21.0%	-51.4%	-1.3%	-17.7%
Enterprise value	$112.2M	$57.6M	-$6.4M	$251.5M	$65.9M	$265M	$61.9M
Net debt / EBITDA	1.83×	0.43×	0.94×	0.64×	4.02×	-2.28×	0.61×
Cash conversion cycle (days)	-440	104	86	27	-119	296	34